Pancreatic Cancer
Advertisement
A recent study compared first-line chemotherapy, as the standard of care for PDAC, with other treatment options.
Entinostat has been utilized in other solid tumors for its ability to induce the inhibition of cell proliferation.
Study participants were administered nadunolimab with a standard dose of gemcitabine and nab-paclitaxel (GN) every two weeks.
Dr. Wungki Park gives an overview of the POLAR study for metastatic pancreatic cancer.
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center discusses his trial on the use of ASP3082 for solid tumors.
The FAK inhibitor narmafotinib targets solid tumors in pancreatic cancer.
mFOLFIRINOX plus CRT did not improve R0 resection nor OS compared with nFOLFIRINOX without CRT.
The primary endpoint was PFS, which was a median of 3.5 months for S-1 and 3.7 months for 5-FU.
Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.
Results showed 64% of patients with HRD mPC were progression-free at 6 months with pembrolizumab and olaparib.
A novel KRAS G12D degrader has an acceptable safety profile and positive antitumor activity, especially in pancreatic cancer.
The use of EUS and multimodal AI across all levels of endoscopic expertise proved beneficial.
While germline testing is recommended for patients with PDAC, many do not undergo testing.
A new cohort study sought to determine the effect of selective surveillance on survival in patients at high risk of PDAC.
Dr. Cecchini explains how ctDNA was used in this study as well as which methods were used for analyzing ctDNA levels.
Research has demonstrated that DC-based immunotherapy resulted in T-cell responses against pancreatic cancer antigens.
Patients with PDAC face difficulty achieving durable disease control when following the current standard of care.
Dr. Faber highlights the implications of increased expression of PDCD1LG2, PDCD1, and HAVCR2 in USC PDAC tumors.
The chimeric antigen receptor-modified T-cell therapy CT041 singles out claudin18.2 in solid tumors.
Dr. Knox details the early results of the PASS-01 trial, which looked at PDAC signature stratification for treatment.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.